Biomimetic Therapeutics — Technical Presentation (March 2010)
25 slides from Biomimetic Therapeutics's technical presentation, Mar 12, 2010
Slide 1: Pivotal Clinical Trial of Augment Bone Graft as a Substitute for Autologous Bone
A Prospective, Randomized, Controlled, Multi-Center Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Bone Graft as a Substitute for Autologous Bone Christopher W. DiGiovanni, MD Sheldon Lin, MD Judith Baumhauer, MD Timothy R. Daniels, MD Alastair S. Younger, MD Mark
Slide 2: Investigator Acknowledgement
Investigator Acknowledgement Nick Abidi Mark Easley Karl-Andre LaLonde Mickey Pinzur David Amirault Frankl Ebert Ian Le Steve Raikin Eric Anctil Andrew Elliott Thomas Lee Gr. Richardson Jorge Acevedo Sam Flemister David Levine D. Richardson Robert Anderson Wm Granberry Thomas Limbird Robt Rochman Do
Slide 3: Study Background
Study Background FUSION well accepted Rx for severe arthritis of hindfoot/ankle Conservatively, @ 10% incidence of delayed/non-union rates: smokers, revisions, post-traumatics, AVN, co-morbidities Autologous Bone Graft is frequently used in these fusions Frey et al 1994, Easley et al 2000, Myerson e
Slide 4: Are We Satisfied With Autograft?
Are We Satisfied With Autograft? Autograft Augmentation does work, BUT Historical results ‘good’…certainly not great Incur donor site pain and morbidity Can add OR/recovery/anaesthesia time How good is it, really? Variable quality and biologic activity Limited supply Cost Why stand still? Promising
Slide 5: Augment Bone Graft
Augment™ Bone Graft (rhPDGF-BB + ß-TCP) Recombinant PDGF (rhPDGF-BB): FDA approved for tissue regeneration applications periodontal bone defects (GEM 21S®) diabetic foot ulcers (Regranex™) Previously evaluated as bone graft substitute pilot studies: foot/ankle, wrist Most recently: Augment™ Bone Gra
Slide 6: Augment North American Pivotal Trial
Augment™ North American Pivotal Trial 434 Randomized Patients, 37 centers (US/CAN) Level I, Prospective, RCT HYPOTHESIS: Augment ™ is non-inferior to ABG when used as a healing adjunct during hindfoot and ankle fusion surgery 1° ENDPOINT: % patients fused by CT scan at 6 mos, as evaluated by blinded
Slide 7: Study Protocol
Study Protocol 2:1 randomization, Augment ™: Autogenous Autograft site @ surgeon discretion (IC, Gerdy’s, distal tib, calc) Std joint preparation, ORIF using ≤ 3 screws/joint Post-op immobilization for 12 wks, NWB first 6 wk Standardized, high definition CT data Independent CT evaluation: 9, 16, 24,
Slide 8: Study Summary
STUDY SUMMARY Substantial percentage of study patients (75%) had one or more risk factors for poor healing (e.g. Diabetes, Smoking, Obesity, Prior Surgery) Rigorous CT scan assessment as the 1° endpoint for bone healing Results for radiologic, clinical, and functional assessments demonstrated compar
Slide 9: Patient Disposition and Evaluability
Patient Disposition and Evaluability Screened Population Not randomized n=457 (456*) *Less one subject screened twice n=21 Randomized Population Not randomized n=435 prior to treatment n=1 ITT Population Not treated n=434 n=20 Augment (285)/Autologous (149) Augment (13)/Autologous (7) Safety Populat
Slide 10: Demographics
Demographics All Patients Augment™ Autograft n= 434 n= 285 n=149 Sex (M/F) 49.8% / 49.1% 46.3% / 52.3% 56.4% / 43.0% Age (Mean) 56.6 years 56.2 years 57.5 years BMI (Mean) 30.8 30.7 31.1 Diagnosis Post Traumatic OA 48.2% 48.8% 47.0% Primary Arthritis 34.3% 32.6% 37.6% Rheumatoid 6.7% 8.4% 3.4% Other
Slide 11: Clinical Example, Ankle
Clinical Example, Ankle
Slide 12: Radiographic Assessment CT Assessment
Radiographic Assessment CT Assessment
Slide 13: Example, Foot
Example, Foot 13
Slide 14: 6 mos CT Assessment
6 mos CT Assessment 14
Slide 15: Results @ 6 months: Radiographic Endpoints
Results @ 6 months: Radiographic Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - Joints 394 203 - - CT Fusion Rate ( 1º endpoint) Full complement of joints 61.2% 62.0% ND 0.038 All joints 66.5% 62.6% ND <0.001 Radiographic Fusion (3 aspects)
Slide 16: Results @ 6 months: Clinical Endpoints
Results @ 6 months: Clinical Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - Joints 394 203 - - Clinically Healed (PI Assess) 83.1% 83.9% ND 0.010 XR, Full Complement 82.3% 83.2% ND 0.011 XR, All Joints 83.5% 83.3% ND <0.001 Delayed Union/No
Slide 17: Results @ 6 months: Functional/Pain Endpoints
Results @ 6 months: Functional/Pain Endpoints Augment P-value (rhPDGF-BB/ß-TCP) Autograft Significance (non- inferiority) Subjects 260 137 - - SF-12 (Mean PCS) 39.9 41.1 ND <0.001 Foot Fusion Index (Mean Total) 27.4 22.3 ND 0.012 AOFAS Ankle-Hindfoot Scale 73.9 75.9 ND <0.001 VAS Pain Scores Fusion
Slide 18: Literature Comparison
Literature Comparison Effectiveness Endpoint Study Population Literature Autograft Reported Augment™ Rates (control) CT Fusion Rate 61.2% 62.0% 64%1 (6 months) 10%2 Nonunion/Delayed Union 8.8% 10.2% 16%3 41%4 AOFAS Hindfoot/Ankle 70.03 73.9 75.9 Overall Score 75.62 1. Coughlin MJ et al, Comparison o
Slide 19: Results @ 6 months: Safety Outcomes
Results @ 6 months: Safety Outcomes P-value Augment Autograft (Fisher Exact (rhPDGF-BB/ß-TCP) Test) Subjects 272 142 Pre-Tx Signs and Symptoms 3.7% 2.8% 0.779 Tx Emergent Adverse Events (TEAE) 72.4% 70.4% 0.730 Serious TEAE 7.7% 14.1% 0.055 Complications (Overall) 33.5% 38.0% 0.386 Complications (Su
Slide 20: Results Summary: Statistically Significant Non-Inferiority
Results Summary: Statistically Significant Non-Inferiority Primary Endpoint: CT Fusion Rate, Full Complement of Joints CT Fusion Rate, All Joints Secondary Endpoints: XR union (3 aspects) for all joints XR union (2 aspects) for all joints Clinical healing: full comp/all joints Non-Union/Delayed Unio
Slide 21: Perspective on Autograft Morbidity
Perspective on Autograft Morbidity Safety benefits trended in favor of Augment ™ group Serious treatment emergent adverse events Complication rates Surgical complications Infection (including one serious infection at ABG harvest site) Augment ™ Bone Graft treated pts had no harvest site morbidity 55
Slide 22: Discussion
Discussion In trying to improve upon the many challenges of bone healing, we need to pay more attention to basic bone biology Currently there are few alternatives that have been shown to be equivalent to autograft in large, randomized controlled trials — and none that are indicated for use in the fo
Slide 23: Study Context
Study Context This study represents Largest prospective RCT ever performed in the subspecialty of Foot and Ankle First to use rigorous, independent, CT analysis as the 1° endpoint Thanks to many people, and many AOFAS members Sufficiently powered to test the hypothesis of non-inferiority to autograf
Slide 24: Osseous Bridging on CT as a Predictor of Clinical Healing
Osseous Bridging on CT as a Predictor of Clinical Healing Osseous bridging =50% a strong predictor of clinical success 96% of patients with =50% osseous bridging on CT scan achieved successful clinical healing (per investigator) Failure to achieve =50% osseous bridging doesn’t necessarily imply clin
Slide 25: Conclusions
CONCLUSIONS Augment ™ Bone Graft demonstrated statistical significance for non-inferiority to autograft Primary radiologic endpoint (CT fusion rate) Key secondary clinical functional, & pain endpoints Augment ™ patients experienced fewer adverse events & complications Radiologic, clinical, and funct
BioMimetic Therapeutics — Technical Presentation (March 2010) on 6ix